Despite evidence that the Bayh-Dole Act has successfully stimulated the translation of academic research to commercial products, the legislation has put a strain on academic-industry relations in the US, mostly due to differences in the bill’s interpretation and implementation, according to participants in a US House of Representatives subcommittee hearing held last week.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.